Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1342010 | 0.81 | — | — | |
| SCHEMBL28248140 | 0.78 | CHRNB2 (0.42) | JAK2JAK1JAK3HSD17B10SMN1; SMN2 | |
| SCHEMBL1340685 | 0.78 | SMN1; SMN2 (0.50) | HPGDJAK2JAK1JAK3HSD17B10 | |
| SCHEMBL1341778 | 0.78 | SMN1; SMN2 (0.55) | HPGDHSD17B10SMN1; SMN2ALDH1A1NAAA | |
| SCHEMBL1341403 | 0.76 | NAAA (0.56) | HPGDHSD17B10SMN1; SMN2NAAAKMT2A | |
| SCHEMBL17923869 | 0.73 | CHRNB2 (0.53) | POLBHPGDHSD17B10ALDH1A1NAAA | |
| SCHEMBL2535622 | 0.73 | GNAI3 (0.57) | POLBHSD17B10SMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL20474688 | 0.73 | NAAA (0.34) | HPGDJAK2JAK1JAK3HSD17B10 | |
| SCHEMBL4257123 | 0.73 | KDM4E (0.40) | HPGDHSD17B10SMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL16225189 | 0.72 | JAK2 (0.34) | HPGDJAK2JAK1JAK3HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648893-B1 | NICOTINE ADDICTION REDUCING HETEROARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2009-09-23 | — | — | EP | disclosed |
| US-7456177-B2 | Heteroaryl fused azapolycyclic compounds which bind to neuronal nicotinic acetylcholine specific receptor sites, and which are useful in modulating cholinergic function, for for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, therapy | PFIZER INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7122534-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1648893-A1 | NICOTINE ADDICTION REDUCING HETEROARYL FUSED AZAPOLYCYCLIC COMPOUNDS | Pfizer Products Inc. (US) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005007655-A1 | NICOTINE ADDICTION REDUCING HETEROARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20050020830-A1 | Heteroaryl fused azapolycyclic compounds which bind to neuronal nicotinic acetylcholine specific receptor sites, and which are useful in modulating cholinergic function, for for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, therapy | PFIZER INC | 2005-01-27 | — | — | US | disclosed |
| US-20040167149-A1 | Aryl fused azapolycyclic compounds | PFIZER INC | 2004-08-26 | — | — | US | disclosed |
| US-6706702-B2 | FOR THERAPY OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | PFIZER INC. | 2004-03-16 | — | — | US | disclosed |
| EP-1076650-B1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030130261-A1 | Aryl fused azapolycyclic compounds | PFIZER INC | 2003-07-10 | — | — | US | disclosed |
| US-20030008890-A1 | Aryl fused azapolycyclic compounds | COE JOTHAM WADSWORTH (US) | 2003-01-09 | — | — | US | disclosed |
| US-6462035-B1 | BINDING TO NEURONAL NICOTINIC ACETYLCHOLINE SPECIFIC RECEPTOR; MODULATING CHOLINERGIC FUNCTION; REDUCING NICOTINE ADDICTION; INFLAMMATORY AND IRRITABLE BOWEL SYNDROME, SPASTIC DYSTONIA, CHRONIC AND ACUTE PAIN, EATING DISORDERS | PFIZER INC. | 2002-10-08 | — | — | US | disclosed |
| EP-1076650-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | Pfizer Products Inc. (US) | 2001-02-21 | — | — | EP | disclosed |
| WO-1999055680-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130261-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN3A | POLB 2859/4885HPGD 2072/4885JAK2 207/4885 |
| US-20050020830-A1 | Heteroaryl fused azapolycyclic compounds which bind to neuronal nicotinic acetylcholine specific receptor sites, and which are useful in modulating cholinergic function, for for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, therapy | CHRNA2, CHRNA3, CHRNB2 | POLB 4365/4885HPGD 1926/4885JAK2 3486/4885 |
| US-20030008890-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, NR3C1 | POLB 3595/4885HPGD 2384/4885JAK2 238/4885 |
| US-20040167149-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, NR3C1 | POLB 3595/4885HPGD 2384/4885JAK2 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.